End-to-End AAV Solutions Viralgen positions as a CDMO offering end-to-end AAV development and manufacturing, including large-scale production, fill-finish, and quality control in GMP-certified facilities in San Sebastián, leveraging AskBio platform tech. This creates a compelling value proposition for gene therapy programs seeking a single partner to accelerate timelines and simplify vendor management.

European Manufacturing Hub With a Spain-based GMP facility, Viralgen provides near-shore European manufacturing, enabling faster regulatory alignment, closer collaboration, and reduced time-to-market for EU and UK programs. Propose targeting European biotech and pharma companies that want regional supply stability and compliance.

Proven Partnerships Recent collaborations with Elaaj Bio, Apertura Gene Therapy, Trogenix, Axovia Therapeutics, and the Broad Institute-linked prion project demonstrate a robust partner network and capability to support diverse indications and modalities. Sales angle: position as collaboration-friendly CDMO able to handle co-development and supply, offer reference cases.

Platform Differentiator The AAV suspension platform and integration with AskBio technology give Viralgen competitive differentiation for handling multiple serotypes and complex gene therapies. Opportunity: pitch as a scalable, versatile manufacturing platform suitable for growing programs, including rare diseases and TfR1 CapX approaches.

Growth Capacity Mid-size firm with revenue in the 10-25M range and a 201-500 employee base, indicating room to scale. Potential to propose capacity agreements, toll manufacturing, or multi-year supply contracts to accommodate pipeline growth, and to explore expansions or additional shuttle manufacturing lines to meet rising demand as more gene therapies advance.